Global Opioid-Induced Constipation Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Opioid-Induced Constipation market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Opioid-Induced Constipation market."
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
North America is the largest Sales place, with a Sales market share nearly 56.48% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 20.49%.

The global Opioid-Induced Constipation market is valued at 2110 million US$ in 2018 is expected to reach 3060 million US$ by the end of 2025, growing at a CAGR of 4.8% during 2019-2025.
This report focuses on Opioid-Induced Constipation volume and value at global level, regional level and company level. From a global perspective, this report represents overall Opioid-Induced Constipation market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Takeda Pharmaceuticals
    Bayer
    Sanofi
    Mallinckrodt
    Salix (Bausch Health)
    AstraZeneca
    Progenics Pharmaceuticals
    Purdue Pharm
    Nektar Therapeutics
    Daiichi Sankyo
    Prestige
    GSK
    Shionogi

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Methylnaltrexone Bromide
    Lubiprostone
    Naloxegol
    Other

Segment by Application
    Hospital
    Pharmacy
    Other